LifeVantage (NASDAQ:LFVN) Now Covered by Analysts at Craig Hallum

Stock analysts at Craig Hallum assumed coverage on shares of LifeVantage (NASDAQ:LFVN) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $35.00 price target on the stock. Craig Hallum’s price objective would suggest a potential upside of 52.17% from the stock’s current price.

Separately, Lake Street Capital assumed coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective for the company.

LifeVantage Stock Up 2.1 %

LFVN opened at $23.00 on Tuesday. The firm has a 50 day moving average price of $15.84 and a 200-day moving average price of $11.63. LifeVantage has a twelve month low of $5.22 and a twelve month high of $24.00. The stock has a market capitalization of $288.08 million, a price-to-earnings ratio of 71.88 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The firm had revenue of $47.21 million during the quarter.

Institutional Trading of LifeVantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFVN. Ritholtz Wealth Management increased its holdings in LifeVantage by 62.0% during the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after buying an additional 10,974 shares during the last quarter. Barclays PLC increased its holdings in LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after buying an additional 11,608 shares during the last quarter. HighTower Advisors LLC purchased a new stake in LifeVantage during the third quarter valued at approximately $638,000. Capital Management Corp VA purchased a new stake in LifeVantage during the third quarter valued at approximately $5,073,000. Finally, Renaissance Technologies LLC increased its holdings in LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after buying an additional 17,300 shares during the last quarter. 35.32% of the stock is owned by hedge funds and other institutional investors.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.